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Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short 
treatment time window comprises major challenges for tissue plasminogen activator 
(tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest 
priorities in the stroke field. This mini review article focuses on our recent efforts aimed 
at evaluating a novel combination approach of low-dose tPA plus recombinant annexin 
A2 (rA2, a tPA, and plasminogen co-receptor), which might enhance tPA thrombolytic 
efficacy, while reducing its associated complications related to intracerebral hemorrhagic 
transformation. Results of our experimental studies using a focal embolic stroke model 
in rats support the feasibility of the combination approach and suggest the potential for 
successful clinical translation.
Keywords: cerebral ischemia, tissue-type plasminogen activator, annexin A2, thrombolysis, combination therapy, 
focal embolic stroke model, rats
Limitations of tPA Thrombolytic Stroke Therapy
By stimulating thrombolysis and rescuing the ischemic brain via restoring blood flow, intravenous 
administration of recombinant tissue plasminogen activator (tPA) remains the most effective inter-
vention with FDA approval for emergency treatment of stroke (Whiteley et al., 2014). However, 
a short treatment time window, hemorrhagic transformation, poor thrombolytic perfusion rate, 
and neurotoxicity comprise the major limitations to its application (Alexandrov and Grotta, 2002; 
Bambauer et al., 2006; Weintraub, 2006). Although other thrombolytic agents are being tested, none 
has been established as effective or as a replacement for tPA (Wang et al., 2004, 2008; Adams et al., 
2007).
Recent clinical investigations have suggested the potential for improving tPA therapy. For 
example, perfusion-/diffusion-weighted imaging (PWI/DWI) mismatch and the diffusion/fluid 
attenuated inversion recovery (DWI/FLAIR) mismatch might have implications in selecting 
patients for reperfusion therapy (Shah et al., 2015; Wouters et al., 2015). A randomized phase 
III trial, ECASS III, designed to test treatment with tPA at 3–4.5  h, showed improved clinical 
outcomes for ischemic patients with thrombolytic treatment (Hacke et al., 2008). However, there 
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was a detectable large difference in odds-ratios between early 
reperfusion (approximately 2.8 OR) and delayed reperfusion 
(approximately 1.4 OR). The benefits of thrombolysis are, thus, 
still heavily dependent on the treatment time, and tPA remains 
associated with increased risk of intracranial hemorrhage and 
reperfusion injury (Hacke et  al., 2008). It has been clinically 
prioritized to seek combination therapies that may extend the 
therapeutic window, reduce tPA-associated hemorrhagic trans-
formation, and improve thrombolytic efficacy (Wang et al., 2004, 
2008; Whiteley et al., 2014).
Pleiotropic effects of exogenous tPA for 
Stroke Reperfusion Therapy
Ischemic stroke is a thrombotic cerebrovascular event. For emer-
gency treatment, intravenous tPA administration is intended 
to reopen occluded vessels by lysis of the thrombus, thereby 
improving clinical outcome through restoration of regional 
cerebral blood flow (CBF), thus salvaging the ischemic brain 
tissues (Fugate and Rabinstein, 2014). One limitation is that tPA 
thrombolysis is only partially or fully successful for re-canali-
zation in about 50% of patients (Hacke et al., 2004). How does 
the ischemic brain respond to tPA in the non-responders within 
the context of weakened vessels and perturbed neurovascular 
homeostasis? Although unequivocal human data are lacking, 
experimental investigations in animal models suggest that tPA 
thrombolytic stroke therapy may have deleterious consequences 
due to the non-thrombolytic actions of tPA (Kaur et al., 2004). 
More investigational efforts are needed to dissect the molecular 
signaling mechanisms initiated by the infused exogenous tPA in 
the occluded vessel and ischemic brain. Accumulating experi-
mental data suggest that exogenous tPA may have additional 
pleiotropic actions within the brain (Kaur et al., 2004), such as 
direct vasoactivity (Nassar et  al., 2004; Armstead et  al., 2009) 
enhanced excitotoxicity (Nicole et al., 2001), and activation of 
extracellular proteases (Nicole et  al., 2001; Wang et  al., 2003, 
2004; Benchenane et  al., 2004; Zeevi et  al., 2007). These non-
thrombolytic actions of tPA may exacerbate edema, increase 
ischemic neurotoxicity, damage the blood–brain barrier, and 
increase risk of cerebral hemorrhage, ultimately compromising 
its usefulness as a thrombolytic agent (Yepes et al., 2003, 2009; 
Su et al., 2008; Armstead et al., 2009).
Re-canalization has been well established as an important 
predictor of better stroke outcome, regardless of thrombolytic 
modality employed. However, a major remaining challenge is 
that exogenous tPA may potentiate ischemia-induced blood–
brain-barrier disruption, increase the risk of symptomatic 
intracranial hemorrhage, which restricts prolonging the thera-
peutic time window (Tsivgoulis et al., 2014). One strategy may 
overcome these dose-dependent side effects of tPA by simply 
lowering the tPA dose, but this step would likely reduce the 
perfusion efficacy. Clearly, an optimization strategy for tPA 
thrombolytic therapy requires rebalancing the potential benefits 
of reperfusion against the detrimental effects of exogenous tPA 
(Wang et al., 2004, 2008).
tPA Receptor Annexin A2 and  
Fibrinolytic Assembly
In fibrinolysis, tPA plays a key role by enzymatically converting 
clot-bound plasminogen to active plasmin, which degrades 
cross-linked fibrin to break down fibrin-containing thrombi. This 
process is called fibrinogenolysis (Ranby and Brandstrom, 1988). 
Interestingly, recent vascular biology studies have demonstrated 
that tPA may interact with cellular receptors to activate specific 
signal transduction pathways (Wang et al., 2008). A new concept 
of fibrinolytic assembly for cell-surface fibrinolysis was proposed, 
in which the tPA conversion of plasminogen to active plasmin is 
precisely orchestrated through a multi-molecular complex, con-
sisting of tPA, the annexin A2 heterotetramer, and plasminogen 
(Kim and Hajjar, 2002).
Annexin A2 is a 36-kDa cell-surface protein, a calcium-
dependent phospholipid-binding protein. In complex with 
its binding partner p11, annexin A2 forms a heterotetrameric 
(A22p112) receptor for both plasminogen, the inactive precursor 
of plasmin, and its activator, tPA (Birnbaum et  al., 1999). The 
assembled complex of tPA–annexin A2– plasminogen increases 
the catalytic efficiency of tPA in converting plasminogen to plas-
min about 60-fold compared with the same amount of tPA alone 
(Hajjar and Menell, 1997; Birnbaum et al., 1999; Kim and Hajjar, 
2002). More experimental evidence suggest that fibrinolytic 
assembly plays a critical role in maintaining blood and vascular 
homeostasis (Hajjar and Acharya, 2000). Additionally, annexin 
A2 exists in both membrane-bound and soluble forms of vas-
cular endothelial cells (Siever and Erickson, 1997), and it can be 
transported to the cell surface in response to cellular stress (Deora 
et al., 2004). Complete deficiency of annexin A2 in mice leads to 
a loss of tPA cofactor activity, intravascular fibrin accumulation, 
and failure to clear arterial thrombi. In sum, these experimental 
findings support an important role of annexin A2 in fibrinolytic 
assembly (Ling et al., 2004).
Manipulating tPA Fibrinolytic Assembly for 
improving Thrombolytic Stroke Therapy
Biologically, tPA efficiently converts plasminogen to clot- 
dissolving plasmin relying on the fibrinolytic assembly of a 
 trimetric complex of tPA–annexin A2–plasminogen. However, 
clinically giving a large amount of tPA alone may lead to inef-
ficient assembly of the tPA–annexin A2–plasminogen complex 
due to a limiting amount of annexin A2. This in turn would 
reduce the efficacy of the tPA in converting plasminogen to 
plasmin, which may be partially responsible for the shortcom-
ings of tPA reperfusion stroke therapy. Thus, “High dose tPA 
required, high hemorrhage risk, low reperfusion efficiency, and 
short therapeutic time window,” which is a major challenge in 
our field, can perhaps be avoided (Lo et  al., 2002; Wang et  al., 
2004). It may revolutionize tPA-based stroke therapy if the tPA 
fibrinolytic assembly can be enhanced and utilized clinically. 
Because plasminogen (plasmin precursor) exists in circulation, 
binds to the endothelial cell surface and is enriched in the clot 
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(Sakharov and Rijken, 1995; Birnbaum et  al., 1999; Hajjar and 
Krishnan, 1999), intravenous tPA combined with annexin A2 will 
locally form tPA–annexin A2–plasminogen complexes and con-
sequently amplify plasmin generation, resulting in more effective 
and specific fibrinolysis (Birnbaum et al., 1999). By translating 
the tPA fibrinolytic assembly into tPA therapy development, we 
hypothesized that combining recombinant annexin A2 protein 
(rA2) will lower the required dose of tPA for reperfusion, while 
enhancing thrombolytic efficacy, and attenuating intracerebral 
hemorrhagic (ICH) transformation. By doing so, it will prolong 
therapeutic time windows and improve long-term outcomes (Fan 
et al., 2010).
experimental investigation of Low-Dose 
tPA Plus rA2 Combination
In the past few years, we have tested this hypothesis in a rat 
focal embolic stroke model. Our experimental findings support 
the feasibility of this approach and suggest clinical translation 
potential (Fan et al., 2010; Zhu et al., 2010; Walvick et al., 2011; 
Wang et al., 2014; Jiang et al., 2015). Consistent with previous 
reports (Cesarman et al., 1994; Kim and Hajjar, 2002), in vitro 
plasmin activity assays showed that rA2 significantly amplified 
tPA-mediated plasmin generation, and equivalent levels of 
in  vitro plasmin activity can be reached by using high-dose 
tPA alone or lower-dose tPA in combination with rA2 (Zhu 
et  al., 2010). Because of species-related differences in fibrin 
specificity, the equivalent effective dose of human recombi-
nant tPA in the rat was about 10 times higher than the dose 
used in humans, or about 10  mg/kg (Korninger and Collen, 
1981). In a focal embolic stroke model in rats, when animals 
were treated intravenously 2 h after initiation of ischemia, the 
25–50% lower-dose tPA plus rA2 combination was as effective 
as the standard high-dose tPA alone in restoring perfusion and 
reducing infarct size (Zhu et al., 2010). This suggests that rA2 
can make low-dose tPA more effective in an embolic stroke 
animal model. Improved reperfusion by the combination was 
confirmed by MRI analysis in focal embolic stroke of rats 
(Walvick et  al., 2011). We extended these promising findings 
by asking whether the benefits of tPA plus rA2 combination 
therapy can be sustained for long-term neurological outcomes. 
We compared the effects of intravenous high-dose tPA alone 
(10  mg/kg) versus a combination of low-dose tPA (5  mg/
kg) plus 10  mg/kg rA2 in a model of focal embolic cerebral 
ischemia in rats treated at 3  h after embolization. Compared 
with conventional high-dose tPA alone, the combination 
significantly decreased infarction (19.6% reduction, P < 0.05) 
and considerably improved neurological function (P < 0.05) at 
1-month after stroke (Wang et al., 2014).
In the most recent experimental study, we asked whether 
the same dose regimen of the combination therapy is still more 
efficacious and safer when the treatment time window is delayed 
to 4 h after stroke (Jiang et al., 2015). Our experimental results 
showed the combination slightly reduced brain infarction com-
pared to saline (9.2% reduction), and tPA (7.4% reduction) at 
24 h after stroke, although the reductions did not reach statistical 
significance, whereas the combination significantly reduced 
(22.2% reduction, P  <  0.05) the conventional tPA-elevated 
ICH transformation. At 7  days after stroke, the combination 
significantly diminished the conventional tPA alone-elevated 
iron deposition in peri-lesion areas (68.2% reduction, P < 0.05). 
At 1 month after stroke, the combination significantly improved 
sensorimotor function recovery (P <  0.05) accompanied by a 
higher microvessel density in the peri-infarct areas compared to 
rats treated with conventional tPA alone group (P < 0.05). Given 
at a 4-h delay time point after stroke, these experimental results 
suggest the low-dose tPA plus rA2 therapy combination pro-
vides a safer profile by lowering the risk of ICH transformation, 
accompanied by an improved neurological function recovery 
after stroke (Jiang et al., 2015). Clinically even within the 3-h 
time window, intravenous tPA only results in partial or complete 
reperfusion to about 50% stroke patients. Unfortunately, we are 
still unable to predict who are the tPA thrombolysis responders 
or non-responders before giving tPA to ischemic stroke patients. 
The 50% non-responders may face a higher risk of tPA thrombo-
lytic therapy-associated ICH transformation, where the 3-month 
mortality was about 60% for ischemic stroke patients who had 
ICH after receiving intravenous tPA administration (Hacke et 
al., 2004). Therefore, the notably lower hemorrhagic transforma-
tion by the combination treatment might reduce mortality and 
improve long-term outcome clinically. Regarding the underly-
ing molecular mechanisms of the better neurological function 
recovery by the delayed combination treatment, we might 
speculate that in addition to the reduction in tPA-associated 
ICH transformation, the lower tPA dose and resulting rA2–tPA 
complex might limit tPA brain penetration-associated neuronal 
excitotoxicity (Yepes et al., 2009), and that rA2 might bind and 
neutralize angiostatin-associated endothelial toxicity (Tuszynski 
et al., 2002), where angiostatin is one of the tPA–plasminogen 
converting products. Ultimately, the decreased hemorrhagic 
brain damage and fewer neurovascular side effects might trans-
late into better vascular remodeling and improvement of long-
term neurological outcome (Fan et al., 2010). We acknowledge 
that both tPA therapy-mediated hemorrhagic risk and functional 
recovery involves complex cascades of BBB, neurovascular and 
gliovascular responses (Jiang et al., 2015), and the full spectrum of 
these associated molecular mechanisms remains to be elucidated 
(Zhang and Chopp, 2009). Some of our ongoing experiments are 
aiming to address these questions.
Since annexin A2 accelerates the activation of plasmin by 
complexing with tPA and plasminogen, and this complex binds to 
the endothelial cell surface and is enriched in the clot (Sakharov 
and Rijken, 1995; Hajjar and Krishnan, 1999), the rA2–tPA 
combination may thus generate more plasmin locally at the clot 
site. Alternatively, within the thrombus, the fibrin-associated 
plasminogen could be activated by A2-associated tPA, resulting 
in more effective fibrinolysis. In addition, rA2-bound tPA and 
plasmin might be relatively protected from their circulating 
inhibitors, plasminogen activator inhibitor-1 (PAI-1), and alpha2-
antiplasmin (alpha2-AP) (Fan et al., 2010). Although the underly-
ing molecular mechanisms for the improved therapeutic efficacy 
by the combination needs to be further elucidated, from a clinical 
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perspective, all these possible mechanisms may ultimately yield a 
rebalancing of tPA thrombolytic reperfusion benefits against its 
detrimental side effects.
Summary
Our experimental investigations provide strong evidence in 
support of the hypothesis that the combination of low-dose tPA 
plus rA2 improves stroke thrombolytic therapy. By improving 
the fibrinolytic assembly to accelerate plasmin generation, thus 
enhancing thrombolytic reperfusion efficacy, the combination 
restores CBF, and rescues ischemic brain tissue more effi-
ciently. This lowers the required dose of tPA, which minimizes 
both tPA-direct and -associated side effects of neurotoxicity, 
FiGURe 1 | Changing the balance of thrombolytic reperfusion benefits versus hemorrhagic side effects of exogenous tPA through the use of a 
low-dose tPA plus rA2 combination. A schematic outline for the potential mechanisms of the combination is to link multiple beneficial and detrimental effects of 
exogenous tPA acting intravascularly and extravascularly. By rebalancing the beneficial/detrimental effect ratio, our new combination approach may improve both 
therapeutic efficacy and safety of tPA-based thrombolytic stroke therapy.
neuroinflammation, extracellular proteolytic dysfunction, and 
hemorrhagic conversion (Fan et al., 2010). Changing the rebal-
ance by improving reperfusion benefits while reducing side 
effects through the combination may diminish the risk of ICH, 
prolong the therapeutic time window, and improve long-term 
outcome of ischemic stroke patients (Figure 1). We acknowledge 
that safety issues and all translational aspects of this potential 
treatment need to be carefully investigated for future preclinical 
evaluation.
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